SCHEMBL1607312

SCHEMBL1607312

Cc1cc(O)c(N=O)c(O)c1N=O

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GRIN2D O15399 1/20 0.40
GRIN3B O60391 1/20 0.40
GRIN1 Q05586 1/20 0.40
GRIN2A Q12879 1/20 0.40
GRIN2B Q13224 1/20 0.40
GRIN2C Q14957 1/20 0.40
GRIN3A Q8TCU5 1/20 0.40
MAPT P10636 9/20 0.39
KMT2A Q03164 7/20 0.39
MEN1 O00255 6/20 0.39
KDM4E B2RXH2 4/20 0.39
USP2 O75604 2/20 0.39
ALDH1A1 P00352 5/20 0.36
HPGD P15428 3/20 0.36
RECQL P46063 3/20 0.36
CYP3A4 P08684 3/20 0.36
ALOX15 P16050 3/20 0.36
MAPK1 P28482 2/20 0.36
NPSR1 Q6W5P4 2/20 0.36
HSD17B10 Q99714 2/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14264481 0.77 GRIN2D (0.40) GRIN2DGRIN3BGRIN1GRIN2AGRIN2B
SCHEMBL3279378 0.77 GRIN2D (0.47) GRIN2DGRIN3BGRIN1GRIN2AGRIN2B
SCHEMBL10388718 0.77 ACHE (0.39) GRIN2DGRIN3BGRIN1GRIN2AGRIN2B
SCHEMBL3280289 0.73 SELL (0.50) GRIN2DGRIN3BGRIN1GRIN2AGRIN2B
SCHEMBL1578480 0.73 KMT2A (0.52) GRIN2DGRIN3BGRIN1GRIN2AGRIN2B
SCHEMBL19596683 0.73 CA1 (0.64) GRIN2DGRIN3BGRIN1GRIN2AGRIN2B
SCHEMBL28321393 0.73 ACHE (0.39) GRIN2DGRIN3BGRIN1GRIN2AGRIN2B
SCHEMBL9437376 0.73 TRPA1 (0.39) GRIN2DGRIN3BGRIN1GRIN2AGRIN2B
SCHEMBL3282798 0.71 ALDH1A1 (0.42) GRIN2DGRIN3BGRIN1GRIN2AGRIN2B
SCHEMBL28157640 0.70 CYP3A4 (0.48) GRIN2DGRIN3BGRIN1GRIN2AGRIN2B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2482809-B1 COMPOSITIONS COMPRISING AN ANTI-INFLAMMATORY BLEND JOHNSON & JOHNSON CONSUMER INC (US) 2018-06-13 EP disclosed
US-9629794-B2 Compositions comprising an NFκB-inhibitor and a tropoelastin promoter JOHNSON & JOHNSON CONSUMER INC. (US) 2017-04-25 US disclosed
EP-2319488-B1 Compositions comprising an NFkB-inhibitor and a tropoelastin promoter JOHNSON & JOHNSON CONSUMER (US) 2016-07-20 EP disclosed
EP-2316413-B1 Compositions comprising an nfkb-inhibitor and a non-retinoid collagen promoter JOHNSON & JOHNSON CONSUMER (US) 2016-07-20 EP disclosed
US-9375395-B2 Compositions comprising an NFκB-inhibitor and a tropoelastin promoter JOHNSON & JOHNSON CONSUMER INC. (US) 2016-06-28 US disclosed
US-9289361-B2 Compositions comprising an NFκB-inhibitor and a non-retinoid collagen promoter JOHNSON & JOHNSON CONSUMER INC. (US) 2016-03-22 US disclosed
US-20150064292-A1 COMPOSITIONS COMPRISING AN NFkB-INHIBITOR AND A TROPOELASTIN PROMOTER KENVUE BRANDS LLC 2015-03-05 US disclosed
US-8906432-B2 Compositions comprising an NFκB-inhibitor and a non-retinoid collagen promoter JOHNSON & JOHNSON CONSUMER COMPANIES, INC. (US) 2014-12-09 US disclosed
US-20130171281-A1 COMPOSITIONS COMPRISING AN NFkB-INHIBITOR AND A TROPOELASTIN PROMOTER JOHNSON & JOHNSON CONSUMER COMPANIES, INC. (US) 2013-07-04 US disclosed
US-20130164393-A1 Compositions Comprising an NFkB-Inhibitor and a Non-Retinoid Collagen Promoter JOHNSON & JOHNSON CONSUMER COMPANIES, INC. (US) 2013-06-27 US disclosed
US-8318217-B2 Compositions comprising an anti-inflammatory blend JOHNSON & JOHNSON CONSUMER COMPANIES, INC. (US) 2012-11-27 US disclosed
EP-2482809-A1 COMPOSITIONS COMPRISING AN ANTI-INFLAMMATORY BLEND Johnson & Johnson Consumer Companies, Inc. (US) 2012-08-08 EP disclosed
EP-2319488-A2 Compositions comprising an NFkB-inhibitor and a tropoelastin promoter Johnson & Johnson Consumer Companies, Inc. (US) 2011-05-11 EP disclosed
EP-2316413-A2 Compositions comprising an nfkb-inhibitor and a non-retinoid collagen promoter Johnson and Johnson Consumer Companies, Inc. (US) 2011-05-04 EP disclosed
US-20110081431-A1 COMPOSITIONS COMPRISING AN NFkB-INHIBITOR AND A NON-RETINOID COLLAGEN PROMOTER KENVUE BRANDS LLC 2011-04-07 US disclosed
US-20110081430-A1 COMPOSITIONS COMPRISING AN NFkB-INHIBITOR AND A TROPOELASTIN PROMOTER JOHNSON & JOHNSON CONSUMER COMPANIES, INC. 2011-04-07 US disclosed
US-20110081433-A1 COMPOSITIONS COMPRISING AN ANTI-INFLAMMATORY BLEND JOHNSON & JOHNSON CONSUMER INC. 2011-04-07 US disclosed
WO-2011041648-A1 COMPOSITIONS COMPRISING AN ANTI-INFLAMMATORY BLEND JOHNSON & JOHNSON CONSUMER COMPANIES, INC. (US) 2011-04-07 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110081431-A1 COMPOSITIONS COMPRISING AN NFkB-INHIBITOR AND A NON-RETINOID COLLAGEN PROMOTER NFKBIA, NFRKB, NFKB1 GRIN2D 4839/4885GRIN3B 4316/4885GRIN1 4307/4885
US-20110081430-A1 COMPOSITIONS COMPRISING AN NFkB-INHIBITOR AND A TROPOELASTIN PROMOTER NFKBIA, NFKB1, NFKB2 GRIN2D 4885/4885GRIN3B 4713/4885GRIN1 4767/4885
US-20150064292-A1 COMPOSITIONS COMPRISING AN NFkB-INHIBITOR AND A TROPOELASTIN PROMOTER NFKBIA, NFKB1, NFKB2 GRIN2D 4885/4885GRIN3B 4713/4885GRIN1 4767/4885
US-20110081433-A1 COMPOSITIONS COMPRISING AN ANTI-INFLAMMATORY BLEND NFKBIA, NFKB2, NFKB1 GRIN2D 3991/4885GRIN3B 2393/4885GRIN1 2403/4885
US-20130171281-A1 COMPOSITIONS COMPRISING AN NFkB-INHIBITOR AND A TROPOELASTIN PROMOTER NFKBIA, NFKB1, NFKB2 GRIN2D 4885/4885GRIN3B 4713/4885GRIN1 4767/4885
US-20130164393-A1 Compositions Comprising an NFkB-Inhibitor and a Non-Retinoid Collagen Promoter NFKBIA, NFRKB, NFKB1 GRIN2D 4839/4885GRIN3B 4316/4885GRIN1 4307/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.